2026-06-26T21:17:44Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/1204032025-05-22T23:49:48Zcom_20.500.14352_14col_20.500.14352_15

Romero Martínez, Manuel Alejandro Ramos Alonso, Eva López-Muñoz, Francisco Gil-Martín, Emilio Escames, Germaine Reiter, Russel J 2025-05-22T14:56:18Z 2025-05-22T14:56:18Z 2022-01 Romero, A., Ramos, E., López-Muñoz, F., Gil-Martín, E., Escames, G., & Reiter, R. J. (2022). Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin?. Cellular and molecular neurobiology, 42(3), 489–500. https://doi.org/10.1007/s10571-020-00938-8 0272-4340 10.1007/s10571-020-00938-8 https://hdl.handle.net/20.500.14352/120403 1573-6830 https://doi.org/10.1007/s10571-020-00938-8 32772307 The world faces an exceptional new public health concern caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), subsequently termed the coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO). Although the clinical symptoms mostly have been characterized, the scientific community still doesn´t know how SARS-CoV-2 successfully reaches and spreads throughout the central nervous system (CNS) inducing brain damage. The recent detection of SARS-CoV-2 in the cerebrospinal fluid (CSF) and in frontal lobe sections from postmortem examination has confirmed the presence of the virus in neural tissue. This finding reveals a new direction in the search for a neurotherapeutic strategy in the COVID-19 patients with underlying diseases. Here, we discuss the COVID-19 outbreak in a neuroinvasiveness context and suggest the therapeutic use of high doses of melatonin, which may favorably modulate the immune response and neuroinflammation caused by SARS-CoV-2. However, clinical trials elucidating the efficacy of melatonin in the prevention and clinical management in the COVID-19 patients should be actively encouraged. eng open access Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin? journal article